Is QURE a good stock to buy? We came across a bullish thesis on uniQure N.V. on r/stocks by AntoniaFauci. In this article, we will summarize the bulls’ thesis on QURE. uniQure N.V.’s share was trading at $20.68 as of May 4th. QURE’s trailing and forward P/E were 2.68 and 5.04 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
uniQure N.V. is a rare disease-focused biotech company developing gene therapies, highlighted by a breakthrough treatment for Huntington’s Disease, a fatal and rapidly degenerative condition with no prior effective therapy. The company demonstrated compelling clinical results, including a 75% reduction in disease progression, significantly extending patient life expectancy and improving quality of life, with anecdotal evidence of delayed disability and even return to work.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Following these results, the stock surged sharply, reflecting the magnitude of the medical advancement. However, this trajectory reversed after Marty Makary, the FDA chair, unexpectedly suspended the approval process without clear justification, creating significant uncertainty. Subsequent public remarks from Makary criticizing gene therapy methodologies, including controversial views on trial design and placebo use in invasive procedures, were widely interpreted as targeting uniQure, further eroding confidence despite unclear alignment with the company’s actual practices.
This regulatory overhang has driven uniQure’s valuation down dramatically from approximately $4.5 billion to around $560 million, leaving the stock trading below its reported cash balance of roughly $690 million. While the downside risk centers on prolonged regulatory obstruction potentially stalling not only this therapy but also the broader pipeline, the situation has drawn bipartisan criticism from policymakers, medical experts, and industry stakeholders, increasing the likelihood of eventual resolution. If regulatory clarity is restored or leadership stance shifts, the stock could re-rate significantly toward prior highs, creating a highly asymmetric risk-reward profile where current valuation is supported by cash while upside depends on external policy reversal.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy’s blockbuster potential, strong pipeline optionality, and improving reimbursement dynamics in gene-editing therapies. CRSP’s stock price has appreciated by approximately 30.77% since our coverage. AntoniaFauci shares a similar view but emphasizes on regulatory risk and valuation dislocation in uniQure N.V. despite breakthrough clinical results.
UniQure N.V. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 66 hedge fund portfolios held QURE at the end of the fourth quarter which was 59 in the previous quarter. While we acknowledge the risk and potential of QURE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than QURE and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
